Drug Delivery Systems: Entering the Mainstream

Science

Volumn 303, Issue 5665, 2004, Pages 1818-1822

  Allen, Theresa M ^a   Cullis, Pieter R ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Inex Pharmaceuticals Corporation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPIDS; NANOSTRUCTURED MATERIALS; POLYMERS; PROTEINS;

DRUG DELIVERY SYSTEMS (DDS); PHARMACOLOGY;

DRUG PRODUCTS;

AMPHOTERICIN B LIPID COMPLEX; ANTIBODY CONJUGATE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BENZOPORPHYRIN DERIVATIVE; CYTARABINE; DENILEUKIN DIFTITOX; DNA; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOLIPOSOME; IMMUNOTOXIN; LIPID; LIPID EMULSION; LIPOSOME; MACROGOL; MICROSPHERE; NANOPARTICLE; PEGADEMASE; PEGINTERFERON ALPHA2B; POLYMER; PRODRUG; RADIOPHARMACEUTICAL AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOSITUMOMAB I 131; VINCRISTINE; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

PHARMACEUTICAL INDUSTRY;

COST BENEFIT ANALYSIS; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXTRAVASATION; DRUG FORMULATION; DRUG RELEASE; DRUG SELECTIVITY; DRUG SOLUBILITY; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG COSTS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; LIPOSOMES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 1642362625     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1095833     Document Type: Review

References (57)

1. M. Liu, K. Kono, J. M. Frechet, J. Control. Release 65, 121 (2000).
2. S. M. Moghimi, A. C. Hunter, J. C. Murray, Pharmacol. Rev. 53, 283 (2001).
3. D. A. LaVan, T. McGuire, R. Langer, Nature Biotechnol. 21, 1184 (2003).
4. R. Duncan, Nature Rev. Drug Discov. 2, 347 (2003).
5. T. M. Allen, Nature Rev. Cancer 2, 750 (2002).
6. J. Huwyler, D. Wu, W. M. Pardridge, Proc. Natl. Acad. Sci. U.S.A. 93, 14164 (1996).
7. R. K. Chowdhary, I. Shariff, D. Dolphin, J. Pharm. Pharm. Sci. 6, 13 (2003).
8. E. M. Bolotin et al., J. Liposome Res. 4, 455 (1994).
9. P. R. Cullis et al., Biochim. Biophys. Acta 1331, 187 (1997).
10. D. W. Northfelt et al., J. Clin. Pharmacol. 36, 55 (1996).
11. P. A. Vasey et al., Clin. Cancer Res. 5, 83 (1999).
12. J. M. Harris, R. B. Chess, Nature Rev. Drug Discov. 2, 214 (2003).
13. A. Gabizon, H. Shmeeda, Y. Barenholz, Clin. Pharmacokinet. 42, 419 (2003).
14. A. Cabanes, K. E. Briggs, P. C. Gokhale, J. A. Treat, A. Rahman, Int. J. Oncol. 12, 1035 (1998).
15. J. M. Meerum Terwogt et al., Cancer Chemother. Pharmacol. 49, 201 (2002).
16. J. Tollemar, S. Andersson, O. Wingden, G. Tyden, Mycoses 35, 215 (1992).
17. K. A. Gelmon et al., J. Clin. Oncol. 17, 697 (1999).
18. P. Tardi et al., Cancer Res. 60, 3389 (2000).
19. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, J. Control. Release 65, 271 (2000).
20. H. Hashizume et al., Am. J. Pathol. 156, 1363 (2000).
21. R. M. Schiffelers, G. Storm, I. A. Bakker-Woudenberg, Pharm. Res. 18, 780 (2001).
22. H. A. Edens et al., J. Immunol. 169, 476 (2002).
23. R. K. Jain, Cancer Metastasis Rev. 6, 559 (1987).
24. P. A. Netti, S. Roberge, Y. Boucher, L. T. Baxter, R. K. Jain, Microvasc. Res. 52, 27 (1996).
25. M. J. Glantz et al., Clin. Cancer Res. 5, 3394 (1999).
26. R. N. Davidson et al., Q. J. Med. 87, 75 (1994).
27. J. Kreuter, Adv. Drug Delivery Rev. 47, 65 (2001).
28. R. Mehvar, Curr. Pharm. Biotechnol. 4, 283 (2003).
29. X. Guo, F. C. J. Szoka, Acc. Chem. Res. 36, 335 (2003).
30. N. M. Bresster, Am. J. Ophthalmol. 133, 168 (2002).
31. D. S. Alberts, D. J. Garcia, Drugs 54, 30 (1997).
32. J. Szebeni et al., J. Liposome Res. 12, 165 (2002).
33. J. Treat, Proc. Am. Soc. Clin. Oncol. 19, 225a (2000).
34. P. D. Senter, C. J. Springer, Adv. Drug Delivery Rev. 53, 247 (2001).
35. B. Uziely et al., J. Clin. Oncol. 13, 1777 (1995).
36. B. L. Samuels, N. J. Vogelzang, M. Ruane, M. A. Simon, Cancer Treat. Rep. 71, 971 (1987).
37. M. Lotem et al., Arch. Dermatol. 136, 1475 (2000).
38. N. Smyth Templeton, Expert Opin. Biol. Ther. 3, 57 (2003).
39. M. Ogris, E. Wagner, Somat. Cell Mol. Genet. 27, 85 (2002).
40. F. Pastorino et al., Clin. Cancer Res., 9, 4595 (2003).
41. S. C. Semple, A. Chonn, P. R. Cullis, Biochemistry 35, 2521 (1996).
42. D. H. Smith et al., Ann. Oncol. 13, 1590 (2002).
43. B. G. Peters, B. J. Goeckner, J. J. Ponzillo, W. S. Velasquez, A. L. Wilson, Formulary 30, 388 (1995).
44. J. Adler-Moore, Bone Marrow Transplant. 14 (suppl. 5), S3 (1994).
45. C. Bory et al., Adv. Exp. Med. Biol. 309A, 173 (1991).
46. L. W. Seymour et al., Int. J. Oncol. 12, 1217 (1998).
47. J. Fang, T. Sawa, H. Maeda, Adv. Exp. Med. Biol. 519, 29 (2003).
48. F. Muggia, A. Hamilton, Eur. J. Cancer 37, S15 (2001).
49. M. J. Glantz et al., J. Clin. Oncol. 17, 3110 (1999).
50. E. Olsen et al., J. Clin. Oncol. 19, 376 (2001).
51. G. Batist et al., J. Clin. Oncol. 19, 1444 (2001).
52. C. Nabhan, M. S. Tallman, Clin. Lymphoma 2, S19 (2002).
53. P. Glue et al., Hepatology 32, 647 (2000).
54. S. Siena et al., Oncol. Rep. 10, 715 (2003).
55. G. A. Wiseman et al., Blood 99, 4336 (2002).
56. M. S. Kaminski et al., J. Clin. Oncol. 19, 3908 (2001).
57. We thank I. MacLachlan, S. Semple, and A. Janse for helpful input.